Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom Regulation topic
No spam. Unsubscribe anytime.
Northampton health board to explore kratom regulation after public testimony of consumer benefit and safety concerns
Summary
After extensive public comment from local and national advocates describing kratom’s role in pain management and recovery, the Northampton Board of Health agreed to gather scientific information, study state models and invite experts before considering local rules such as age limits and behind‑the‑counter requirements.
Dozens of public commenters told the Northampton Board of Health that kratom is a life‑saving, plant‑based treatment for chronic pain and addiction-recovery support, while board members and legal counsel described a mixed scientific and regulatory picture and asked for technical briefings before making regulatory decisions.
The lede: Amanda Rainer, a resident and kratom user, told the board she has used kratom for eight years and credited it with replacing more than 50,000 prescribed pharmaceutical pills and improving her health. “I am asking you to please allow me and allow everyone else here, whether they use it for sobriety, they use it to manage their day to day life,” Rainer said during the public-comment segment.
The nut graf: The board heard several consistent themes — powerful personal testimony of benefit; concerns about adulterated products, concentrated formulations and synthetics; existing state-level variability (some towns have bans or restrictions); and limited federal action that leaves much regulatory authority to states and local health boards.
Public commenters included people who described long-term kratom use tied to recovery or chronic-pain management. Andrea Heickert said her brother and sister survived fentanyl/carfentanil overdoses and that kratom supported long-term sobriety for family members. “It is because of Kratom's ability to take the place of high profit pharmaceuticals and be used as an exit substance,” Dylan Smith said. Advocates urged regulation rather than a ban, proposing age limits and placing kratom behind counters.
Suzanne Smith (board member) summarized state context and scientific uncertainty. Suzanne told the board she found conflicting data and cited CDC and news analyses: according to presented figures, the CDC-linked review identified kratom as a contributing factor in more than 4,000 overdose deaths from 2022 to 2024 (about 1.4% of overdoses in that period), while a 2022 review of 30 states found only 56 deaths solely attributable to kratom in that year and that many kratom‑involved fatalities also included other substances.
The board discussed enforcement options used in other towns. Cheryl Sabara (Massachusetts Association of Health Boards) noted that Needham and other municipalities regulate or ban synthetic cannabinoids and that Needham has regulated synthetic kratom; she also recommended age restrictions and behind‑the‑counter sales as a minimum approach. Amy (health staff) reported local retail-survey results showing kratom in a small number of outlets with retail prices ranging from about $9 to $90 and a mix of powders, capsules, tablets and liquids; some adult-only stores kept kratom behind counters.
Board members agreed on a next step: invite independent scientific presenters, including people familiar with the Kratom Consumer Protection Act and industry testing standards, to brief the board on dosing, contaminants, and certification processes before any regulatory action. The board did not vote on a ban or a regulatory amendment; rather, members asked staff to identify experts from the American Kratom Association or other testing bodies and return with materials at a future meeting.
